Orion Oyj

OVERVIEW |  NEWS |  MULTIMEDIA  | RESEARCH

---

Orion Oyj Company Summary

COMPANY DATA

	Homepage	www.orion.fi

---

Key Developments: Orion Oyj

	Orion Oyj (HEL:ORN1V) Orion Comments On ANDA Filed By Wockhardt Limited For A Generic Version Of Orion's Proprietary Drug Stalevo® In The United States NOV 3, 2008 16:33 - Article Views: 709 Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent
	Orion Oyj (HEL:ORN1V) Composition Of The Nomination Committee Of Orion Corporation OCT 30, 2008 01:51 - Article Views: 471 Orion Oyj (HEL:ORN1V) The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company: Kari Jussi Aho Matti Kavetvuo Timo Maasilta Timo Ritakallio Jukka Ylppö.
	Orion Oyj (HEL:ORN1V) Orion Group Interim Report 1-9/2008 OCT 28, 2008 21:19 - Article Views: 1,760 Orion Oyj (HEL:ORN1V) Orion's net sales in January-September 2008 stood at EUR 530.1 million (1-9/2007: EUR 509.6 million), up by 4.0% on the comparative period of January-September 2007.
	Orion Oyj (HEL:ORN1V) Orion Corporation's Publication Schedules For Financial Reporting In 2009 OCT 28, 2008 21:15 - Article Views: 336 Orion Oyj (HEL:ORN1V) Orion Corporation will publish its financial result for 2008 on Friday, 6 February 2009.
	Orion Oyj (HEL:ORN1V) Orion Publishes Interim Report 1-9/2008 On 28 Oct 2008 OCT 17, 2008 15:33 - Article Views: 454 Orion Oyj (HEL:ORN1V) Orion Corporation will publish its Interim Report for the period of January-September 2008 on Tuesday 28 October 2008 at 8:30 EET. The release and the presentation material will be available after publication on the Group's homepage at www.orion.fi/investors.
	Orion Oyj (HEL:ORN1V) Orion Comments On New ANDA By Sun Pharma Global, Inc. For Generic Entacapone (Orion's Proprietary Drug Comtan®) In The United States OCT 8, 2008 02:15 - Article Views: 414 Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent
	Orion Oyj (HEL:ORN1V) Orion Updates Progress With Dexmedetomidine Trials SEP 12, 2008 19:37 - Article Views: 329 Orion Oyj (HEL:ORN1V) With this release, Orion Corporation updates information provided earlier on the Phase III clinical studies which are under way with dexmedetomidine, a sedative for patients in intensive care, with an aim to have the product registered in Europe as a long-term infusion, administered for over 24 hours. In these studies, the efficacy and safety of dexmedetomidine is compared with sedatives currently used in intensive care, i.e. midazolam in the MIDEX study and propofol in the PRODEX study, altogether in approximately 1,000 patients.
	Orion Group Interim Report 1-6/2008 AUG 5, 2008 19:27 - Article Views: 372 Orion Oyj Steady growth continued
	500,000 Orion A-shares Converted Into B-shares JULY 28, 2008 17:33 - Article Views: 284 Orion Oyj In accordance with Section 3 of the Articles of Association of Orion Corporation, 500,000 A-shares have been converted into 500,000 B-shares. The conversion has been entered into the Trade Register on 28 July 2008. After the conversion there are 51,440,668 A-shares and 89,817,160 B-shares in the company.
	Orion Corporation Publishes Interim Report Q2/2008 On 5 August 2008 JULY 23, 2008 17:01 - Article Views: 392 Orion Oyj Orion Corporation will publish its Interim Report for the period of January-June 2008 on Tuesday, 5 August 2008. The estimated time of disclosure is 12.00 Finnish time. The release and the presentation material will be available after publishing on the Group's homepage at www.orion.fi/investors.

228 COMPANY PROFILE VIEWS

This Page Viewed: (Last 30 Days: 3) (Since Published: 228)